other_material
confidence high
sentiment negative
materiality 0.75
Denali Capital receives Nasdaq delisting determination; must appeal by April 9 or face suspension
Semnur Pharmaceuticals, Inc.
- On April 2, 2025, Nasdaq staff determined Denali failed to meet MVLS, total assets, and public float rules.
- Company must appeal by April 9, 2025 to avoid delisting; if no appeal, trading suspended April 11, 2025.
- Company expects to trade on OTC market after delisting; plans to remain a reporting company.
- Delisting not expected to immediately impact planned business combination with Semnur Pharmaceuticals.